Exec Edge

By Karen Roman Suja Life, Inc. (Nasdaq: SUJA) said second quarter net sales increased 11.6% from a year ealier to $83.9 million, driven by volume growth and new product distribution gains. Gross profit rose 9.9% from a year ago to $39.2 million, or 46.7% of net sales, it stated. Suja also updated its 2026 fiscal outlook and now expects net sales of $360 – $369 million compared to $326.6 million in 2025, it said.

Tech Edge hosted a fireside chat on July 27 at Nasdaq MarketSite with David Gerry, Chief Executive Officer of Bugcrowd.

Tech Edge hosted a fireside chat on July 27 at Nasdaq MarketSite with Dan Kramer, Chief Executive Officer of Equiniti. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed what has to be true for a share to be tokenized and still count as a real share since not all tokens work the same way.

Download the Complete Report Here Rice Royalty Conversion, Precision-Breeding Platform, and BioFragrance Scale-Up Support Commercial Inflection CBUS is an asset-light precision-breeding platform that develops productivity traits for seed-company partners, rather than owning seed production, distribution or farmer relationships. RTDS® and the Trait Machine™ process are designed to edit elite customer germplasm and return partner-ready material for commercialization.

Download the Complete Report Here Cibus, Inc. (CBUS) Rice Royalty Conversion, Precision-Breeding Platform, and...

By Exec Edge Editorial Staff Inside enterprises actually deploying AI at scale, a different answer is emerging. The companies seeing the strongest results are not removing humans from the process. They are redesigning how humans and AI work together. That shift is becoming one of the defining trends in enterprise communications and customer engagement.

Download the Complete Report Here ALPHA-01 Moves to Revenue Generation; $21-23 Million Run Rate and Expanding Pipeline Support Scale-Up Key Takeaways: FY26 largely reflects legacy strategic phases; ALP’s live compute operations and contracted revenue provide the more relevant basis for assessing its growth trajectory.

By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as the company advances its lead candidate toward clinical trials, it said.

By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of life sciences leadership experience, including serving as CFO of Verona Pharma, where he helped guide the company through Phase 3 trials, FDA approval, and the commercial launch of Ohtuvayre before its $10 billion acquisition by Merck in 2025.

By Daniella Parra Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) said its Enhanced Brain Delivery (EBD) bispecific antibodies showed improved brain penetration in the treatment of Alzheimer’s disease. The company said it is collaborating with JCR Pharmaceuticals Co., Ltd. on EBD candidate development and studies through transferrin receptor-mediated delivery across both mouse and non-human primate models.